SEARCH

SEARCH BY CITATION

References

  • 1
    Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004; 22: 10814.
  • 2
    Fennerty MB. Medical treatment of gastroesophageal reflux disease in the managed care environment. Semin Gastrointest Dis 1997; 8: 909.
  • 3
    Lundell L, Dent J, Bennett J, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17880.
  • 4
    Katelaris P, Holloway R, Talley N, et al. Gastro-oesophageal reflux disease in adults: guidelines for clinicians. J Gastroenterol Hepatol 2002; 17: 82533.
  • 5
    Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11(Suppl. B): 66B73B.
  • 6
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 7
    Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 116.
  • 8
    Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005; 54: 74651.
  • 9
    Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 73946.
  • 10
    Junghard O, Wiklund I. Validation of a four-graded scale for severity of heartburn in patients with symptoms of gastroesophageal reflux disease. Value Health 2008; 11: 76570.
  • 11
    Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 148793.
    Direct Link:
  • 12
    Labenz J, Armstrong D, Nauclér E, Eklund S. Predictors of healing of reflux esophagitis: results from the EXPO study [abstract]. Gut 2005; 54: A110.
  • 13
    Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 261620.
    Direct Link:
  • 14
    Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 5319.
  • 15
    Wilder-Smith C, Backlund A, Eckerwall G, et al. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease : a randomized, dose-response study. Clin Drug Investig 2008; 28: 33343.
  • 16
    Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 19: 58794.
  • 17
    Gillessen A, Beil W, Modlin I, et al. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004; 38: 33240.
  • 18
    Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 190020.
    Direct Link:
  • 19
    Tytgat GNJ, Lee A, Graham DY, Dixon MF, Rokkas T. The role of infectious agents in peptic ulcer disease. Gastroenterol Int 1993; 6: 7689.
  • 20
    Manes G, Balzano A. Peptic ulcer, Helicobacter pylori, and reflux symptoms. Gastrointest Endosc 2003; 57: 2889.
  • 21
    Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults – update 2004. Can J Gastroenterol 2005; 19: 1535.
  • 22
    Malfertheiner P, Mégraud F, O’Morain C. Current concepts in the management of Helicobacter pylori infection – the Maastricht III Consensus Report. Gut 2007; 56: 77281.
  • 23
    Verdu EF, Armstrong D, Fraser E, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 53945.
  • 24
    Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of esomeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 72532.
  • 25
    Gillen D, Wirz AA, Neithercur WD, et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 46875.
  • 26
    Van Soest E, Siersema P, Dieleman J, et al. Adherence and persistence to proton pump inhibitors in daily clinical practice [abstract]. Gastroenterology 2006; 130(Suppl. 2): A-14.
  • 27
    Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34: 18594.
  • 28
    Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19: 91127.
  • 29
    Hasselgren G, Hassain-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40: 14550.
  • 30
    Venables T, Newland D, Patel A, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-esophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 31
    Lauritsen K, Devière J, Bigard M-A, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: metropole study results. Aliment Pharmacol Ther 2003; 17: 33341.
  • 32
    Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 108: 261928.
    Direct Link:
  • 33
    Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354: 23408.
  • 34
    Sheu BS, Cheng HC, Chang WL, et al. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis. Am J Gastroenterol 2007; 102: 238794.
    Direct Link:
  • 35
    Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 96571.
  • 36
    Rex D, Cummings O, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 16707.
  • 37
    Lin M, Gerson LB, Lascar R, et al. Features of gastroesophageal reflux disease in women. Am J Gastroenterol 2004; 99: 14427.
    Direct Link: